Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma

Journal of Clinical Oncology

Volumn 14, Issue 11, 1996, Pages 3018-3025

  Lemoli, R M ^a   Rosti, G ^a   Visani, G ^a   Gherlinzoni, F ^a   Miggiano, M C ^a   Fortuna, A ^a   Zinzani, P ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HEMOGLOBIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD CELL COUNT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029805097     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.11.3018     Document Type: Article

References (38)

1. Nemunaitis J, Rabinowe S, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
2. Gulati SC, Bennett CL: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 116:177-182, 1992
3. Linch DC, Scarffe H, Proctor S, et al: Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11:307-311, 1993
4. Stahel RA, Jost LM, Cerny T, et al: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12:1931-1938, 1994
5. Nemunaitis J, Appelbaum FR, Singer JW, et al: Phase I trial with recombinant human interteukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood 82:3273-3278, 1993
6. Fibbe WE, Raemakers J, Verdonck LF et al: Human recombinant interleukin-3 after autologous bone marrow transplantation for malignant lymphoma. Ann Oncol 3:163, 1992 (abstr)
7. Rabinowe S, Nemunaitis J, Armitage J, et al: The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol 28:6-16, 1991 (suppl 1)
8. Metcalf D: Hematopoietic regulators: Redundancy or subtlety? Blood 82:3515-3523, 1993
9. Oster W, Schultz G: Interleukin-3: Biological and clinical effects. Intern J Cell Cloning 9:5-23, 1991
10. Ikebuchi K, Clark SC, Ihle JN, et al: Granulocyte colony-stimulating factor enhances interleukin-3-dependent proliferation of multipotential hematopoietic progenitors. Proc Natl Acad Sci USA 85:3445-3449, 1988
11. Leary AG, Zeng HG, Clark SC, et al: Growth factor requirement for survival in G0 and entry into the cell cycle of primitive human hematopoietic progenitors. Proc Natl Acad Sci USA 89:4013-4017, 1992
12. Jacobsen SEW, Ruscetti FW, Dubois CM, et al: Induction of colony-stimulating factor receptor expression on hematopoietic progenitor cells: Proposed mechanism for growth factor synergism. Blood 80:678-687, 1992
13. Ulich TR, del Castillo J, Mc Niece IK, et al: Acute and subacute hematologic effect of multi-colony stimulating factor in combination with granulocyte colony-stimulating factor in vivo. Blood 75:48-53, 1990
14. Seiler FR, Krieter H, Mac Vittie T, et al: Preclinical studies on the efficacy of CSFs in dogs and subhuman primates, in Murphy MJ (ed): Blood cell growth factor: Their present and future use in hematology and oncology. Symposium, Beijing, China. Dayton, OH, AlphaMed Press, 1991, pp 40-59
15. Tepler I, Hamm JT, Shulman L, et al: Combination cytokine therapy with recombinant human interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF) after "ICE" chemotherapy for lung cancer: Sequential and simultaneous schedules. Proc Am Soc Clin Oncol 12:333, 1993 (abstr)
16. Wolff SN, Ahmed T, Van Besien K, et al: Simultaneous and sequential rhIL-3 (SDZ ILE 964) and rhG-CSF (Neupogen) post autologous bone marrow transplantation (ABMT) for lymphoma: A phase I-II study. Blood 82:287a, 1993 (suppl 1, abstr 1134)
17. Mazza P, Zinzani PL, Martelli M, et al: MACOP-B vs F- MACHOP regimen in the treatment of high-grade Non-Hodgkin's lymphomas. Leuk Lymphoma 16:457-463, 1995
18. Gerhartz HH, Mandelli F, Philip T, et al: Randomized phase III study of interleukin-3 (rhIL-3) in IEV chemotherapy of relapsing aggressive lymphomas. Blood 86:54a, 1995 (suppl 1, abstr 202)
19. Santoro A, Viviani S, Valagussa P, et al: CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 13:23-27, 1986
20. Benini C, Bandini G, Motta MR, et al: Donor origin of hematopoiesis after a case of allogeneic transplantation with cryopreserved marrow. Haematologica 78:414, 1993
21. Lemoli RM, Fortuna A, Motta MR, et al: Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87:1625-1634, 1996
22. Miggiano MC, Gherlinzoni F, Visani G, et al: Hematological recovery after autologous bone marrow transplantation for high-grade non Hodgkin's lymphomas: A single center experience. Haematologica 79:225-232, 1994
23. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 341:1051-1054, 1993
24. Gulati SC, Yahalom J, Portlock C: Autologous bone marrow transplantation. Current Probl Cancer 15:5-56, 1991
25. Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666-676, 1990
26. Donahue RE, Seehra J, Metzger M, et al: Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241:1820-1823, 1988
27. Mayer P, Valent P, Schmidt G, et al: The in vivo effects of recombinant human interleukin-3: Demonstration of basophil differentiation factor, histamine-producing activity, and priming of GMCSF-responsive progenitors in nonhuman primates. Blood 74:613-621, 1989
28. Patchen ML, Fischer R, MacVittie TJ: Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia. Exp Hematol 21:338-344, 1993
29. Ganser A, Lindemann A, Ottmann OG, et al: Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulat ing factor) as a new therapeutic modality to stimulate hematopoiesis: Results of a phase I study. Blood 79:2583-2591. 1992
30. Brugger W, Frisch J, Schulz G, et al: Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 10:1452-1459, 1992
31. Fay JW, Lazarus H, Herzig R, et al: Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A phase l/II multicenter study. Blood 84:2151-2157, 1994
32. Fay JW, Felser JM, Abboud C, et al: Sequential administration of recombinant human interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) after autologous bone marrow transplantation (ABMT) therapy for lymphoma: Results of a phase III multi-center study. Blood 86:222a, 1995 (suppl 1, abstr 875)
33. Lemoli RM, Fortuna A, Fogli M, et al: Proliferative response of human marrow myeloid progenitor cells to in-vivo treatment with granulocyte colony-stimulating factor (G-CSF) and G-CSF in combination with interleukin-3 (IL-3) after autologous bone marrow transplantation (ABMT). Exp Hematol 23:1520-1526, 1995
34. Crump M, Couture F, Kovacs M, et al: Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Exp Hematol 21:405-410, 1993
35. Weisdorf DJ, Verfaillie CM, Davies SM, et al: Hematopoietic growth factors for graft failure after bone marrow transplantation: A randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 85:3452-3456, 1995
36. Chao NJ, Schriber JR, Long GD, et al: A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF ) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 83:2823-2828, 1994
37. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cells "mobilized" by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
38. Chao NJ, Schriber JR, Grimes K, et al: Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031-2035, 1991